Endothelial Cell Clinical Trial
— IL-33Official title:
Regulation of IL33, Endocan and Their Targets in Primary Human Endothelial Cells
| Verified date | November 2022 |
| Source | University Hospital, Lille |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The study aims to investigate the inflammatory response of endothelial cells to various stimulations, in particular the production of IL33 and of endocan in response to allergens, agonists of microorganisms and pollutants. For that purpose, this project attempts to set up a biological collection of lung and umbilical cord endothelial cells. Lung endothelial cells are resected from a surgical specimen, resulting from a lung cancer surgery. Umbilical cord-derived endothelial cells are taken from the umbilical cord collected during the delivery.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | November 8, 2021 |
| Est. primary completion date | November 8, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Age > 18 years - signed consent - Pregnant woman for umbilical cord-derive-endothelial cells Exclusion Criteria: - Age < 18 years - Refusal to participate to the study - Endothelial cord-drived endothelial cells : - significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) - infection for HIV, VHB, VHC - unknown status for HIV, VHB, VHC the day of the childbirth. |
| Country | Name | City | State |
|---|---|---|---|
| France | Hop Calmette Chu Lille | Lille |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Lille |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells. | change from Baseline at 48 hours after stimulation | ||
| Secondary | change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells. | change from Baseline at 4 hours, 12h ours, 24 hours after stimulation | ||
| Secondary | change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells. | change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation | ||
| Secondary | change in IL33 protein concentration between stimulated and unstimulated primary human lung endothelial cells. | change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation | ||
| Secondary | change in IL33 protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells. | change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation | ||
| Secondary | change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells. | change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation | ||
| Secondary | change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells. | change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation | ||
| Secondary | change in endocan protein concentration between stimulated and unstimulated primary human lung endothelial cells. | change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation | ||
| Secondary | change in endocan protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells. | change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation |